Chronic Lymphocytic Leukemia | Clinical

Roundtable Discussion: Pagel Walks Through Treatment Choices in Chronic Lymphocytic Leukemia

January 16, 2022

During a Targeted Oncology live event, John M. Pagel, MD, PhD, and participants discussed their experiences with BTK inhibitors such as acalabrutinib and ibrutinib in terms of efficacy and tolerability as well as other treatment options in patients with chronic lymphocytic leukemia.

Zanubrutinib/Venetoclax Shows Efficacy in High-Risk CLL Subgroup

January 05, 2022

Jennifer R. Brown, MD, PhD, discusses the interim results of the SEQUOIA trial , which investigated the combination of zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.